Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

Gómez-Peralta, Fernando; Lecube, Albert; Fernández-Mariño, Ana I.; Troncoso, I Alonso; Morales, Cristóbal; Morales-Pérez, F M; Guler, Ipek; Cadarso‐Suárez, Carmen

doi:10.1111/dme.13769

Cited by 10 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gomez-Peralta et al found a positive correlation between weight reduction and a higher baseline weight, longer duration of treatment with liraglutide, and the interaction between time and concomitant metformin [25]. Another real-world study found lower HbA1c reductions in patients who initiated insulin either before or around the same time as starting a GLP-1RA [30].…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review

Yousef

Thomas

Matar

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Different patterns of response have been attributed to factors such as age, liraglutide dose, baseline HbA1c, duration of T2DM, and concomitant treatments. A higher baseline HbA1c, longer duration of T2DM, and longer duration of insulin treatment have been shown to counter the effects of liraglutide [25,29].…”

Section: Discussionmentioning

confidence: 99%

Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review

Yousef

Thomas

Matar

et al. 2021

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…To date, numerous studies have examined characteristics associated with weight loss response to obesity pharmacotherapies (Table 3). A majority of these investigations involve orlistat [71][72][73][74][75][76] and GLP-1 receptor agonists (GLP1-RAs) [77][78][79][80][81][82][83][84][85] in individuals with overweight/obesity, or topiramate in individuals with seizure disorders with or without obesity. [86][87][88][89] Studies evaluating hormonal, genotypic, and neuronal predictors of weight loss response are rare.…”

Section: Pharmacotherapymentioning

confidence: 99%

“…91 Specifically, in adults with type 2 diabetes mellitus (T2DM) prescribed GLP1-RAs, a lower hemoglobin A1c level seems to predict an improved weight loss response. 78,83 Further, a higher baseline weight status, 80,84 longer duration of treatment, 80 and previous use of dipeptidyl peptidase journals.sagepub.com/home/tae 13 4 inhibitors 84 have also been associated with better weight loss outcomes. Overall, while some predictors of weight loss response to obesity pharmacotherapy have been uncovered, there is a myriad of others yet to be elucidated.…”

Section: Pharmacotherapymentioning

confidence: 99%

Precision medicine in adult and pediatric obesity: a clinical perspective

Bomberg

Ryder

Brundage

et al. 2019

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

It remains largely unknown as to why some individuals experience substantial weight loss with obesity interventions, while others receiving these same interventions do not. Person-specific characteristics likely play a significant role in this heterogeneity in treatment response. The practice of precision medicine accounts for an individual’s genes, environment, and lifestyle when deciding upon treatment type and intensity in order to optimize benefit and minimize risk. In this review, we first discuss biopsychosocial determinants of obesity, as understanding the complexity of this disease is necessary for appreciating how difficult it is to develop individualized treatment plans. Next, we present literature on person-specific characteristics associated with, and predictive of, weight loss response to various obesity treatments including lifestyle modification, pharmacotherapy, metabolic and bariatric surgery, and medical devices. Finally, we discuss important gaps in our understanding of the causes of obesity in relation to the suboptimal treatment outcomes in certain patients, and offer solutions that may lead to the development of more effective and targeted obesity therapies.

show abstract

“…Thus, it is likely that sequential initiation would be the more commonly adopted approach, including Patient #1 in whom liraglutide was started followed by SGLT2 inhibitor, and Patient #2 in whom liraglutide was added to existing SGLT2 inhibitor therapy. Gomez et al [15] found that a greater reduction in HbA1c and weight was observed when GLP-1 agonist was added to existing treatment with an SGLT2 inhibitor, rather than vice versa [13]-which was the approach in Patient #2.…”

Section: Discussionmentioning

confidence: 99%

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination

Chua

2021

Clinics and Practice

View full text Add to dashboard Cite

Sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) agonists are important drugs in our armamentarium of treatment for Type 2 diabetes mellitus (DM). In addition to their glucose-lowering effects, they have effects on weight, other metabolic diseases and perhaps most importantly, a cardioprotective and reno-protective effect. Liraglutide is a long-acting GLP-1 agonist which was originally used at 1.8 mg daily for the treatment of DM. However, high-dose liraglutide—liraglutide 3 mg daily, has been demonstrated to be a safe and effective treatment for obesity, with or without DM. In this manuscript, I present two patients who had unusual responses to combination therapy with high-dose liraglutide and SGLT2 inhibitor—marked and/or rapid improvement in glycemic control and weight loss. Drawing from the observations in both cases, I discuss the complementary mechanisms of actions of both drugs, review the clinical effects of combination therapy and distil them into clinical pearls of practical utility for the physician. Given the “clash of the two pandemics” of obesity and COVID-19 and the burgeoning rates of obesity which loom in the near horizon, this is most timely.

show abstract

Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real‐world retrospective study conducted in Spain

Cited by 10 publications

References 29 publications

Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review

Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review

Precision medicine in adult and pediatric obesity: a clinical perspective

High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination

Contact Info

Product

Resources

About